Hengrui PharmaceuticalS SHR6390 approved clinical lying for the treatment of recurrent or metastatic breast cancer

yesterday, it was revealed that HengruiMedicine(http://SHR6390 tablets approved for clinical use in the combination of fluorovis group treatment HR-positive, HER2-negative after endocrine therapy progression of recurrent or metastatic breast canceras well as recurrent or metastatic breast cancer used to treat HR-anaquzole in combination with HR-anaquzole, HER2-negative, endocrine-based progressionAbout SHR6390
SHR6390 is a CDK4/6 selective inhibitor for the treatment of malignant tumorsThe world's first CDK4/6 inhibitor, adeveloped by PfizerInc.,(http:// was approved by theFDA(http://in February 2015 through accelerated review and is now available in the European Union, Japan and other countries and regions, the FDA has approved three CDK 4/6 inhibitorsdrug (http:// , including Pfizer's Palbociclib (2015/2/3), Novartis' Ribociclib (2017/3/13) and Lilly's Abemaciclib (2017/9/28), with global sales of $41.18, 235.55 billion in 2018 　　At present, only Pfizer's a CDK4/6 inhibitor was approved for market, and a total of 25 drug declarations in other CDK4/6 inhibitors in research were declared clinical or in clinical stage, while The SHR6390 tablets of Hengrui Pharmaceuticals were preemptively entered Phase III clinical studies